Cytogenotoxic effects of fullerene C60 in the freshwater teleostean fish, Anabas testudineus (Bloch, 1792)

Publication date: Available online 26 September 2019Source: Mutation Research/Genetic Toxicology and Environmental MutagenesisAuthor(s): Nechat Sumi, Kumari Chidambaran ChitraAbstractIn recent years, carbon nanomaterials, including fullerene C60 is regarded as the building block in nanotechnology because of its widespread use in medicine, industry, cosmetics and commercial products. Despite the special properties, several reports have raised public health concerns due to the unknown and practically unexplored toxic effects of nanomaterials. However, there have been relatively few studies regarding the genotoxic responses of fullerene C60 in vivo. Genotoxic effects of DMSO-solublized C60 nanomaterial suspension at sublethal concentrations (5 and 10 mg/ L) were investigated on adult freshwater fish, Anabas testudineus using micronucleus and comet assays. An assessment of micronucleus induction showed severe cytoplasmic and nuclear abnormalities in erythrocytes, gill and liver cells. Abnormalities in cytoplasm were identified as formation of sticky cells, vacuolated cytoplasm, cytoplasmic degeneration, echinocyte, acanthocyte, anisochromatic cells and abnormal erythrocyte membrane. The nuclear abnormalities included micronucleus, binucleated cells, nuclear buds, irregular nucleus, vacuolated, notched and serrated nucleus in the erythrocytes compared to the control groups. Similarly, significant increase (P 
Source: Mutation Research Genetic Toxicology and Environmental Mutagenesis - Category: Genetics & Stem Cells Source Type: research

Related Links:

CONCLUSION: Extensive research have been carried out on various process for preparing Bortezomib and composition thereof. This type of dynamic research will clear the path for many generic players in the United States which lead in reduction of price of the composition and thereby enhancing global health care at cheaper prices. PMID: 32234004 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
FDA has granted Emergency Use Authorization (EUA) to Battelle's CCDS Critical Care Decontamination System for processing up to 80,000 respirator masks per system each day. CCDS employs concentrated, vapor-phase hydrogen peroxide (VPHP) for decontamination. The system has been validated to decontaminate masks of SARS-CoV-2, the company reported. The masks are placed on shelves inside a container, and a portable, external VPHP system is hooked up to the outside of container. The system was first envisioned by Battelle as part of a study commissioned by FDA in 2015. That study involved determining the feasibility of N95 respi...
Source: MDDI - Category: Medical Devices Authors: Tags: Sterilization Source Type: news
Source: BMJ Comments - Category: General Medicine Source Type: forums
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Jorge A Alfaro-Murillo, Marí L Ávila-Agüero, Meagan C Fitzpatrick, Caroline J Crystal, Luiza-Helena Falleiros-Arlant, Alison P Galvani
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Stephen W Russell, Brian T Garibaldi, Andrew Elder, Abraham Verghese
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s):
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Fathiah Zakham, Olli Vapalahti, Hilal A Lashual
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Renato D Lopes, Claudio Gimpelewicz, John J V McMurray
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Genichi Sugihara, Nori Takei
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Gorka Orive, Unax Lertxundi
Source: The Lancet - Category: General Medicine Source Type: research
More News: Environmental Health | Fish | Genetics | International Medicine & Public Health | Liver | Nanotechnology | Study | Toxicology | Urology & Nephrology